Two trials presented at ISTH 2020 attest to the safety and efficacy of the bispecific monoclonal antibody emicizumab as a prophylactic agent in people with haemophilia A (PwHA) with factor VIII (FVIII) inhibitors.
The overall rates of bleeding and recurrent venous thromboembolism (VTE) were low across various subgroups after 12 months of edoxaban treatment in routine clinical practice, according to a non-interventional, post-authorization safety study of edoxaban — ETNA-VTE* presented during the ISTH 2020 Meeting.
Treatment with apixaban led to a significantly reduced risk of venous thromboembolism (VTE) among ambulatory cancer patients who were undergoing chemotherapy, according to two post hoc analyses of the AVERT* trial presented at the ISTH 2020 Meeting.
Thrombotic complications are rife among in-hospital patients with COVID-19, with patients in the ICU particularly at risk compared with those in the general wards, a study released at the ISTH 2020 Meeting has shown.
The direct oral anticoagulant apixaban may help prevent deaths when given at prophylactic or therapeutic doses in hospitalized COVID-19 patients with elevated D-dimer levels, according to an analysis presented during the ISTH 2020 Congress.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.